ClinicalTrials.gg
CompletedNCT03161626Updated Nov 12, 2021

Registry Study of COAGADEX® Patients With Moderate or Severe Hereditary Factor X Deficiency Undergoing Major Surgery

An observational study in Factor 10 Deficiency, sponsored by Bio Products Laboratory. Completed at 3 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2021-11-12.

Sponsored by Bio Products Laboratory · Observational

Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
3
Ages
12 Years and older
Sex
All
01

Study summary

This is a non-interventional, multicenter, post-marketing registry study in three patients with moderate or severe hereditary FX deficiency, to assess Coagadex administered peri-operatively for hemostatic cover in major surgery during routine post-marketing use.

Read the detailed description

The primary objective is to collect additional surgical data on the clinical effectiveness of Coagadex, in a post-marketing environment, for peri-operative hemostatic cover during major surgery in patients with moderate or severe hereditary factor X (FX) deficiency.

The secondary objective is to review safety data on Coagadex through the collection of any Adverse Drug Reactions (ADRs) from the first dose of Coagadex in the hospital prior to the surgical procedure until the first follow-up after discharge (i.e., follow-up completed) and Serious ADRs up until the post-operative care follow-up has been completed. Data on any deaths and pregnancies reported within this time period will be collected.

02

Conditions studied

  • Factor 10 Deficiency
03

In context

Lead sponsor

Bio Products Laboratory is the lead sponsor of 27 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with moderate or severe hereditary Factor X deficiency undergoing major surgery.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients >12 years of age with severe or moderate hereditary FX deficiency. Severe is defined as \<1 IU/dL and moderate as 1 to 5 IU/dL (3)
  • Patients who have given written (for sites in the USA this will include the Health Insurance Portability and Accountability Act (HIPAA) authorization statement), OR, in the case of 12-18 year olds, written informed consent from the parents/ guardians and where appropriate assent from the child
  • Patients requiring major surgery. Major surgery is defined as procedures typically requiring:

    • full anesthesia or regional anesthesia, e.g. epidural or spinal and
    • involving the opening of major cavities such as thoracic, abdominal surgery; orthopedic surgery, and Caesarean section (C-section) and
    • requiring at least one overnight stay in hospital (16)

Exclusion criteria

Exclusion Criteria:

  • Patients known to be pregnant, unless the surgery is C-section.
  • Patients who participated in a clinical study trial in the last 30 days prior to study enrolment, except if they have been involved in another study involving Coagadex.
  • Patients with a known history of inhibitor development to FX.
  • Patients who are required or expected to take other factor X-containing medications during or after surgery.
  • Patients with existing known thrombocytopenia ( \< 50 x 109/L).
  • Patients with existing known renal disease (creatinine >200 µmol/L).
  • Patients with existing known clinically significant liver disease ( levels greater than three times the ).
  • Patients with existing known other coagulopathy or thrombophilia.
  • Patients with a known intolerance or allergy to Coagadex or its .
  • Patients known to have abused chemicals or drugs within the past 12 months.
  • Patients with a history of unreliability or non-cooperation.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.

05

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
3 participants (actual)
Patient registry
No

Groups and cohorts

  • Moderate to Severe Factor X Deficiency

    Drug: Coagadex

Interventions

  • Plasma-driven blood coagulation factor X concentration

    Also known as: Factor X

06

What researchers measure

Primary outcomes

  1. Retrospective surgical data collection

    Blood loss (mL)

    Time frame: 12 months

07

Study locations

3 sites
  • University of Florida Health
    Gainesville, Florida 32610, United States
  • Tulane University Hospitals and Clinics
    New Orleans, Louisiana 70112, United States
  • West Michigan Cancer Center
    Kalamazoo, Michigan 49007, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 12, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03161626
Lead sponsor
Bio Products Laboratory
Responsible party
Sponsor
First posted
May 22, 2017
Start date
Feb 27, 2018
Primary completion
Oct 13, 2021
Completion
Oct 13, 2021
Last update
Nov 12, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion